Recent Developments and the Effect of Antiangiogenic and Chemotherapeutic Nano formulations for Combination Cancer Therapy

As tumor growth and metastasis are frequently dependent on tumor vascularization, conventional chemotherapy in combination with antiangiogenesis medicines (combination cancer therapy) has demonstrated reduced tumor recurrence and better antitumor effects. But the effectiveness of combination chemotherapy-including synergistic, additive, and even antagonistic effects-depends on the optimal medication ratios in the combination. The combination therapy of chemo-antiangiogenesis for cancer is therefore excellent, and Nano formulations show a great deal of promise in this regard. Different Nano carriers for combination therapy have been designed with organic (polymer, lipid), inorganic, or hybrid materials as the basis. Particularly flexible for different forms of entrapment within the same carrier, such as physical adsorption, encapsulation, and chemical conjugation techniques, is hybrid Nano carriers made of multiple material constructs. Thus, chemo- and antiangiogenesis medicines can be delivered together with customizable drug release at target areas using these multifunctional Nano carriers. Therefore, this study aims to assess the most recent developments in Nano formulations and their influence on the combination of traditional cytotoxic and antiangiogenesis drugs in the treatment of cancer. Future prospects as well as the mechanisms and site-specific co-delivery options are covered here.